Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
2(25%)
Results Posted
50%(3 trials)

Phase Distribution

Ph phase_1
2
25%
Ph phase_2
1
13%
Ph phase_3
5
63%

Phase Distribution

2

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
1(12.5%)
Phase 3Large-scale testing
5(62.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(6)

Detailed Status

Completed6
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 21 (12.5%)
Phase 35 (62.5%)

Trials by Status

recruiting113%
completed675%
active_not_recruiting113%

Recent Activity

2 active trials
Showing 5 of 8
recruitingphase_2

Personalized Therapies in Inflammatory Complex Disease

NCT03651518
completedphase_3

Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT05335356
active_not_recruitingphase_3

An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis

NCT06488664
completedphase_1

A Safety and Pharmacokinetics Study of Ustekinumab Biosimilar GNR-068 and Stelara® in Healthy Volunteers

NCT06481215
completedphase_3

Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT04785326
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03651518Phase 2

Personalized Therapies in Inflammatory Complex Disease

Recruiting
NCT05335356Phase 3

Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis

Completed
NCT06488664Phase 3

An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis

Active Not Recruiting
NCT06481215Phase 1

A Safety and Pharmacokinetics Study of Ustekinumab Biosimilar GNR-068 and Stelara® in Healthy Volunteers

Completed
NCT04785326Phase 3

Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis

Completed
NCT05890118Phase 1

Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule

Completed
NCT04673786Phase 3

A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis

Completed
NCT04930042Phase 3

Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis

Completed

All 8 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8